Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion.
Am J Surg
; 217(4): 739-744, 2019 04.
Article
em En
| MEDLINE
| ID: mdl-30103903
ABSTRACT
BACKGROUND:
Microvascular invasion (MVI) has recently been reported to be an independent prognostic factor in patients with hepatocellular carcinoma (HCC). This study compared the outcomes of adjuvant transarterial chemoembolization (A-TACE) after hepatic resection (HR) in patients with HCC involving MVI.METHODS:
This prospective study involved 200 consecutive patients with MVI-HCC who underwent HR alone (nâ¯=â¯109) or HR with A-TACE (nâ¯=â¯91).The Kaplan-Meier method was used to compare disease-free survival (DFS) and overall survival (OS).RESULTS:
The two groups showed similar DFS at 1, 2, and 3 years (Pâ¯=â¯0.077). The A-TACE group showed significantly higher OS than the HR-only group (Pâ¯=â¯0.030). Subgroup analysis showed that A-TACE was associated with significantly higher DFS and OS among patients with a tumor diameter >5â¯cm or with multinodular tumors.CONCLUSIONS:
A-TACE may improve postoperative outcomes for MVI-HCC patients, especially those with tumor diameter >5â¯cm or multinodular tumors.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quimioembolização Terapêutica
/
Carcinoma Hepatocelular
/
Neoplasias Vasculares
/
Neoplasias Hepáticas
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article